20:29 , Jul 16, 2019 |  BC Extra  |  Financial News

July 16 Financial Quick Takes: J&J growth drivers beat consensus; plus Notable and Cradle raise funds

Imbruvica, Darzalex sales top analysts' consensus  In its 2Q19 earnings report, Johnson & Johnson (NYSE:JNJ) said revenue from its pharmaceutical segment grew to $10.53 billion during the quarter, up 1.7% compared with 2Q18, with newer...
15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
10:32 , Apr 22, 2019 |  BC Extra  |  Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment. Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive...
20:45 , Feb 8, 2019 |  BC Week In Review  |  Company News

Verily launches OneFifteen to create tech-forward solutions for addiction

Verily Life Sciences LLC (South San Francisco, Calif.) launched OneFifteen, a not-for-profit healthcare "ecosystem" that includes clusters for innovators to develop technology-enabled solutions for patients suffering from opioid addiction. Verily said it will develop a...
00:53 , Sep 15, 2018 |  BioCentury  |  Politics, Policy & Law

Debating diagnostics

Instead of perpetuating a decades-old dispute about whether FDA can and should regulate laboratory-derived tests, the agency and test makers have moved on to conversations about how FDA should do so, and from threats of...
18:54 , Jul 13, 2018 |  BC Week In Review  |  Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million on July 12 in the final tranche of its series A round, bringing the round's total to $132 million. OrbiMed Advisers led the round....
15:35 , Jul 12, 2018 |  BC Extra  |  Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million Thursday in the final tranche of its series A round, bringing the round's total to $132 million. OrbiMed Advisers led the round. F-Prime Capital...
13:48 , Apr 13, 2018 |  BC Week In Review  |  Company News

Alexandria LaunchLabs expanding to Cambridge, Mass.

Alexandria Real Estate Equities Inc. (NYSE:ARE) said it will expand Alexandria LaunchLabs to Cambridge, Mass. LaunchLabs is designed to provide life science start-ups with office space, equipment, amenities and access to investment capital. Last year,...
04:19 , Apr 12, 2018 |  BC Extra  |  Financial News

Alexandria LaunchLabs expanding to Cambridge, Mass.

Alexandria Real Estate Equities Inc. (NYSE:ARE) said it will expand Alexandria LaunchLabs to Cambridge, Mass. LaunchLabs is designed to provide life science start-ups with office space, equipment, amenities and access to investment capital. Last year,...